ACME-PORTABLE
2.3.2015 09:16:12 CET | Business Wire | Pressemeddelelse
The network and mobile market is constantly in research and development mode. Engineers, solution providers, and analysts are competing to provide better services to customers, exceed expectations, and present new technologies to their market.
Because these efforts have increased complexity and workspace, professionals are in of need an efficient, quick-to-use, and complete portable solution.
"We detected the demand for this solution by listening to our customers and we took the challenge to develop portables unified with compactness and highest performance in a box ," says James Cheng, CEO of ACME Portable. "If you need a lightweight solution with high-end hardware, if you have limited workspace and work in multiple locations, or if you need a compact tool for on-site analysis, ACME Portable has the solution for you."
ACME Portable has developed two leading products for networking applications - the MiniPAC, the entry-level version, and the NetPAC, the enterprise version.
These portable systems are managed by a high-performance RAID controller for the fastest read/write speeds and can support the latest networking capturing cards. The NetPAC and MinPAC are high-performance hardware tools that combine the latest technologies to offer high-speed data capture with real-time analytics and visualization.
They can be used for many applications, including but not limited to
• Network analysis
• Write to Disk
• Lossless packet Capture
• Network Traffic Simulation or replay
• Various traffic forensic analysis applications
• Compact LTE / 4G / 3G tool
• Protocol Analyser
• Network stress testing.
Product specifications Highlights
• Up to 64TB of SSD/SAS/SATA drives with RAID support for NetPAC and up to 16TB for MiniPAC
• Newest and maximum memory capabilities
• Network traffic capturing for 1G,10G,20G,40G & 100G
• Up to 4 PCIe full-length expansion cards regardless power demands
• Supports all card interfaces
• Latest processing power with i7/Dual Xeon CPUs
• Easy transport
• Optional OEM customization
The products could be modified upon request with customer-specific features including hardware design, custom color and design, private label branding, and any operating system or application. Our goal is to help you create your own innovative product as a unique solution to your market.
We would like to open up new possibilities for you and your customers and improve your Return of Investment. To learn more about our product, contact us using one of the options below:
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150302005382/en/
Contact:
ACME Portable
Mr. Timos Tamvakis
Tel-EU: 00497215704530
Tel-US:
0016266101888
info@acmeportable.de
,
sales@acmeportable.com
www.acmeportable.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum